The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Official Title: Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
Study ID: NCT04202341
Brief Summary: Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Detailed Description: At the time of enrollment in the Registry, participant records will be queried for retrospective information about the participants' medical history and gMG disease treatment history. Following enrollment, prospective data collection will be performed using data obtained as part of the routine clinical care and through patient-reported outcome methods in use. Data will be collected using an electronic data capture system. The duration of data collection for the Registry will be up to 5 years from the day of enrollment.
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Clinical Trial Site, Birmingham, Alabama, United States
Clinical Trial Site, Phoenix, Arizona, United States
Clinical Trial Site, Fresno, California, United States
Clinical Trial Site, Rancho Mirage, California, United States
Clinical Trial Site, Sylmar, California, United States
Clinical Trial Site, Colorado Springs, Colorado, United States
Clinical Trial Site, Fort Collins, Colorado, United States
Clinical Trial Site, New Haven, Connecticut, United States
Clinical Trial Site, Clearwater, Florida, United States
Clincal Trial Site, Gainesville, Florida, United States
Clinical Trial Site, Tampa, Florida, United States
Clinical Trial Site, Augusta, Georgia, United States
Clinical Trial Site, Lake Barrington, Illinois, United States
Clinical Trial Site, Iowa City, Iowa, United States
Clinical Trial Site, Lexington, Kentucky, United States
Clinical Trial Site, Boston, Massachusetts, United States
Clinical Trial Site, Lansing, Michigan, United States
Clinical Trial Site, Las Vegas, Nevada, United States
Clinical Trial Site, New Hyde Park, New York, United States
Clinical Trial Site, Chapel Hill, North Carolina, United States
Clinical Trial Site, Durham, North Carolina, United States
Clinical Trial Site, Dayton, Ohio, United States
Clinical Trial Site, Philadelphia, Pennsylvania, United States
Clinical Trial Site, Dallas, Texas, United States
Clinical Trial Site, Houston, Texas, United States
Clinical Trial Site, Burlington, Vermont, United States
Clinical Trial Site, Milwaukee, Wisconsin, United States